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background: VEGF-Receptor-1 mediates cytoprotective mechanisms, therefore its selective agonist VEGF-B could be an ideal candidate for the 
therapy of dilated cardiomyopathy, which is characterized by high rate of apoptosis in the absence of major coronary lesions. The aim of this study 
was to test clinically relevant methods of cardiac gene therapy with adeno-associated virus (AAV)-mediated VEGF-B delivery in a large animal model 
of dilated cardiomyopathy.
Methods: Nineteen chronically instrumented dogs were subjected to high-frequency cardiac pacing for 4 weeks to induce heart failure and were 
divided into 3 groups receiving intracoronary infusion of AAV9-VEGF-B167 as follows: 1) 10^13 VEGF-B under the control of the spontaneously active 
CMV promoter (n=10), 2) 2x10^13 CMV-VEGF-B (n=5), 3) 4x10^13 of VEGF-B controlled by the ANF promoter that, although weaker than CMV, is 
activated in ventricles only in response to pathological conditions (n=4). Ten pacing dogs received 10^13 AAV9-GFP and served as control heart 
failure as well as to determine the transduction efficacy by GFP staining.
results: The transduction efficiency in LV myocardium displayed heterogeneous distribution (1%-50%) from epi- to endocardial layers. At 4 weeks, 
CMV-VEGF-B gene transfer markedly preserved cardiac function compared to the GFP control heart failure group: LV end-diastolic pressure was 
12.2±4.8 vs. 24.83±3.4mmHg, dP/dtmax 2112±665 vs. 1457±478mmHg/sec and EF 43±4 vs. 30±5% (all P<0.05). Cardiac function was preserved 
even further when twice as much CMV-VEGF-B was administered (EDP 12.2±6.9mmHg; dP/dtmax 2610±383mmHg/sec; EF 46±4%; P<0.05). 
Finally, ANF-VEGF-B was less effective than CMV-VEGF-B, but still attenuated cardiac dysfunction compared to control (EDP 18.8±8mmHg; dP/dtmax 
1865±337mmHg/sec; EF 37±4%; P<0.05).
conclusion: These results show marked therapeutic effects of VEGF-B transgenes administered with standard invasive methods in a pre-clinical 
model of dilated cardiomyopathy and call for further implementations of endogenously controlled gene constructs.
